НИПТ стандартная панель (анеуплоидии 13, 18, 21, X, Y хромосом)

The Noninvasive Prenatal Testing (NIPT) standard panel assesses cell-free DNA in maternal blood to estimate the risk of common fetal aneuploidies: trisomy 21, trisomy 18, trisomy 13, and sex chromosome aneuploidy. This is a screening assay rather than a diagnostic test; results guide referral for genetic counseling and consideration of confirmatory diagnostic procedures.

Human development begins at fertilization, when a zygote forms and a stable, individualized genetic complement is established. During early embryogenesis, organ primordia emerge, growth accelerates, and differentiation proceeds within a genetically unique organism. Observational reports describe early cardiac activity and circulatory function by roughly 18–21 days post‑conception; limb buds take shape by 4 weeks, and early digit formation is noted by approximately 5½ weeks. Spontaneous fetal movements have been observed by about 6½ weeks, with nociceptor development reported by 7 weeks alongside detectable neural activity; by this time, external and internal organs are described as present in early forms. Between 4 and 8 weeks, recognizable hands, feet, facial features, and eyes are identifiable, and by 8 weeks the fetus may exhibit brief movements (for example, contacting the uterine wall) and cycles of activity and rest, with somatic systems functioning in early stages. From 8 to 12 weeks, organogenesis approaches completion and head, body, and limb movements increase; facial movements, mouth opening, and swallowing of amniotic fluid are observed on ultrasound. Hair growth begins around 9–10 weeks, and by 10 weeks ocular structures are formed though the eyes remain closed under small eyelids. By approximately 11 weeks, facial expressions such as frowning or smiling are recorded, and organ systems continue to mature. By about the 10th gestational week, maternal blood contains sufficient circulating cell‑free fetal (placental) DNA to support noninvasive prenatal testing. The NIPT standard panel analyzes a mixture of maternal cell‑free DNA and placental DNA to estimate risk for specific chromosomal abnormalities—trisomies 21, 18, and 13, and aneuploidies of the X and Y chromosomes. A high‑risk result indicates increased probability but does not establish a diagnosis; genetic counseling is recommended. The test does not evaluate all genetic or nongenetic conditions. A negative (low‑risk) result does not exclude all abnormalities of chromosomes 21, 18, 13, or the sex chromosomes, including microdeletions or microduplications of small genomic regions. When ultrasound demonstrates fetal, umbilical cord, or placental abnormalities, the standard NIPT panel may be uninformative; such findings can reflect other chromosomal disorders, monogenic disease, or nonchromosomal causes. In these situations, consultation with a medical geneticist is advised.